ASTRIA THERAPEUTICS INC (ATXS) Stock News

USA - NASDAQ:ATXS - US04635X1028 - Common Stock

7.46 USD

+0.18 (+2.47%)

Last: 10/1/2025, 1:47:42 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ATXS Latest News, Press Relases and Analysis

All

Press Releases

14 days ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology

22 days ago - By: Zacks Investment Research

Wall Street Analysts Believe Astria Therapeutics (ATXS) Could Rally 294.75%: Here's is How to Trade

23 days ago - By: Zacks Investment Research

Astria Therapeutics, Inc. (ATXS) Now Trades Above Golden Cross: Time to Buy?

a month ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025

a month ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference

2 months ago - By: Zacks Investment Research

Does Astria Therapeutics (ATXS) Have the Potential to Rally 333.88% as Wall Street Analysts Expect?

2 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

2 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan

2 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit

3 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit

4 months ago - By: Benzinga - Mentions: PRE CPHI TLSA HCTI ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

4 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress

4 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress

4 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Astria Therapeutics

Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference

4 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop

4 months ago - By: Astria Therapeutics

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

5 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

5 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology

5 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference

6 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

7 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

7 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

7 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

7 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference

7 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress

8 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

8 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference

8 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session

8 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

9 months ago - By: Astria Therapeutics, Inc.

Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE